Background:
The aim of the current study was to evaluate the outcomes and complications of three-unit porcelain-fused-to-metal tooth-implant-supported prostheses in comparison with implant-supported prostheses.
Materials and Methods:
In this review article, the electronic databases, PubMed, Scopus, LILACS, Web of Science, EBSCO, LIVIVO, and Embase were searched over the past 20 years until December 2021. Risk ratio with 95% confidence interval (CI), fixed effect model, and Mantel–Haenszel method was calculated. The meta-analysis was performed with the statistical software Stata/MP v. 16.
Results:
Two hundred and three studies were selected for reviewing the abstracts, from which the full texts of 16 studies were reviewed. Finally, five studies were selected. The risk ratio of prosthesis failure between the tooth-implant-supported prosthesis and the implant-supported prosthesis was RR (Risk Ratio)= 1.83 (0.79, 4.24), (
P
= 0.16) and for prosthesis complication, it was RR = 0.61 (0.35, 1.06), (
P
= 0.08). Risk ratio of implant failure between the mentioned groups was RR = 2.33 (0.84, 6.41), (
P
= 0.10), and for implant complications, this rate was 0.09 (RR, 0.09 95% CI − 1.30, 1.48;
P
= 0.90).
Conclusion:
The meta-analysis of the present study showed that there was no significant difference between the two groups (three-unit porcelain-fused-to-metal tooth-implant-supported prosthesis and implant-supported prosthesis reconstruction) in terms of the total failure of implants and prostheses and the complication rate of implants and prostheses.
Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) that have entered clinical applications. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy drugs with one RTKI or multiple RTKIs) especially for drug resistant cancers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.